CL2008000330A1 - Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades. - Google Patents

Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades.

Info

Publication number: CL2008000330A1
Authority: CL; Chile
Prior art keywords: compounds; fenantreno; octahidro; dermatitis; alzheimer
Prior art date: 2007-02-02

Application number

CL200800330A

Other languages

English (en)

Inventor

Venkateswaran Devraj Ga Rajesh

Original Assignee

Pfizer Products Inc Sa Organiz

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-02

Filing date

2008-02-01

Publication date

2008-08-08

2008-02-01 Application filed by Pfizer Products Inc Sa Organiz filed Critical Pfizer Products Inc Sa Organiz

2008-08-08 Publication of CL2008000330A1 publication Critical patent/CL2008000330A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)

CL200800330A 2007-02-02 2008-02-01 Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades. CL2008000330A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88798107P	2007-02-02	2007-02-02

Publications (1)

Publication Number	Publication Date
CL2008000330A1 true CL2008000330A1 (es)	2008-08-08

Family

ID=39315208

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL200800329A CL2008000329A1 (es)	2007-02-02	2008-02-01	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades.
CL200800330A CL2008000330A1 (es)	2007-02-02	2008-02-01	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL200800329A CL2008000329A1 (es)	2007-02-02	2008-02-01	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades.

Country Status (43)

Country	Link
US (7)	US7547714B2 (es)
EP (1)	EP2114970B1 (es)
JP (1)	JP4599462B2 (es)
KR (2)	KR101107949B1 (es)
CN (2)	CN101616925B (es)
AP (1)	AP2455A (es)
AR (2)	AR065134A1 (es)
AT (1)	ATE518872T1 (es)
AU (1)	AU2008211613B2 (es)
BR (1)	BRPI0808634A2 (es)
CA (1)	CA2676670C (es)
CL (2)	CL2008000329A1 (es)
CO (2)	CO6220937A2 (es)
CR (2)	CR10948A (es)
CU (2)	CU20090133A7 (es)
CY (2)	CY1110962T1 (es)
DK (1)	DK2114970T3 (es)
DO (1)	DOP2009000190A (es)
EA (1)	EA016494B1 (es)
EC (2)	ECSP099553A (es)
ES (2)	ES2368286T3 (es)
GE (2)	GEP20125404B (es)
GT (2)	GT200900210A (es)
HK (1)	HK1135108A1 (es)
HN (2)	HN2008000178A (es)
HR (1)	HRP20110702T1 (es)
IL (1)	IL199972A (es)
MA (2)	MA31117B1 (es)
MX (1)	MX2009008284A (es)
MY (3)	MY146087A (es)
NI (2)	NI200900149A (es)
NZ (1)	NZ578638A (es)
PE (2)	PE20081736A1 (es)
PL (1)	PL2114970T3 (es)
PT (2)	PT2114970E (es)
RS (2)	RS51970B (es)
SI (1)	SI2114970T1 (es)
SV (2)	SV2009003346A (es)
TN (1)	TN2009000324A1 (es)
TW (2)	TWI347842B (es)
UA (2)	UA94639C2 (es)
WO (1)	WO2008093227A1 (es)
ZA (2)	ZA200906064B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU228426B1 (hu)	1996-07-24	2013-03-28	Warner Lambert Co	Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására
EP2114970B1 (en)	2007-02-02	2011-08-03	Pfizer Products Inc.	Tricyclic compounds and their use as glucocorticoid receptor modulators
KR101377860B1 (ko) *	2008-07-28	2014-03-25	화이자 인코포레이티드	페난트렌온 화합물, 조성물 및 방법
WO2010059894A1 (en) *	2008-11-21	2010-05-27	Bridge Pharma, Inc.	Ocular formulations of norketotifen
US20100136094A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100137246A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Anti-inflammatory compositions and methods
US20100136097A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100135983A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Anti-inflammatory compositions and methods
US20100137787A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Delivery devices for modulating inflammation
US20100136095A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100136096A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
AU2011251622A1 (en)	2010-05-10	2012-12-20	Radikal Therapeutics Inc.	Lipoic acid and nitroxide derivatives and uses thereof
JP2013536250A (ja) *	2010-08-27	2013-09-19	コーセプトセラピューティクス，インコーポレイテッド	ピリジル−アミン縮合アザデカリンモジュレーター
KR20140015472A (ko) *	2011-03-15	2014-02-06	애브비 인코포레이티드	핵 호르몬 수용체 조절제
US8545904B1 (en)	2012-06-05	2013-10-01	Liquid Innovators, LLC	Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en)	2012-07-05	2016-01-05	Abbvie Inc.	Process for preparing bicyclic amine derivatives
TW201422590A (zh)	2012-09-07	2014-06-16	Abbvie Inc	雜環核激素受體調節劑
WO2014094357A1 (en)	2012-12-21	2014-06-26	Abbvie Inc.	Heterocyclic nuclear hormone receptor modulators
KR101787310B1 (ko)	2014-05-16	2017-10-18	리퀴드 인코포레이티드	케라틴 처리 제형 및 방법
ES2848977T5 (es)	2014-10-20	2024-06-06	Oyster Point Pharma Inc	Métodos de tratamiento de afecciones oculares
CN104591988A (zh) *	2014-12-29	2015-05-06	甘肃省化工研究院	6-溴-2-萘满酮的合成方法
CN113350353A (zh)	2015-03-23	2021-09-07	墨尔本大学	呼吸性疾病的治疗
PT3439661T (pt)	2016-04-07	2021-09-30	Oyster Point Pharma Inc	Métodos de tratamento de condições oculares

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2576025B1 (fr)	1985-01-14	1987-01-23	Roussel Uclaf	Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) *	1986-06-19	1988-08-26	Pechiney Aluminium	Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
IL122740A (en)	1997-01-15	2003-09-17	Akzo Nobel Nv	16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
CZ304203B6 (cs)	1999-04-30	2014-01-02	Pfizer Products Inc.	Modulátor glukokortikoidního receptoru a léčivo pro léčbu zánětlivé choroby s jeho obsahem
WO2001005229A1 (en)	1999-07-15	2001-01-25	The General Hospital Corporation	Non-defective epstein-barr viral vector
IL180679A0 (en) *	2000-10-27	2009-02-11	Pfizer Prod Inc	Process for the preparation of non-steroidal glucocorticoid receptor modulators
EP1201649B1 (en) *	2000-10-28	2006-05-31	Pfizer Products Inc.	Glucocorticoid receptor modulators
ES2246292T3 (es)	2000-10-30	2006-02-16	Pfizer Products Inc.	Moduladores de receptor glucocorticoide.
DE10196880T1 (de) *	2000-11-20	2003-12-18	Seagate Technology Llc	RF-ID-Tag-Attachment an ein Plattenlaufwerk
MXPA03011935A (es)	2001-06-22	2004-03-26	Pfizer Prod Inc	Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
IL160649A0 (en)	2001-08-31	2004-07-25	Corcept Therapeutics Inc	Methods for inhibiting cognitive deterioration in adults with down syndrome
ATE426593T1 (de)	2001-09-27	2009-04-15	Univ Liege	Pyridinsulfonamidderivate, deren herstellungsverfahren und verwendung
DE10164366C1 (de) *	2001-12-28	2003-06-05	Rehau Ag & Co	Permanentkathode
ES2305434T3 (es)	2002-02-01	2008-11-01	Pfizer Products Inc.	Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
CA2491296C (en)	2002-07-02	2012-05-22	Corcept Therapeutics, Inc.	Methods for treating psychosis associated with interferon-.alpha. therapy
PT1521733E (pt)	2002-07-08	2014-10-29	Pfizer Prod Inc	Moduladores do recetor de glucocorticoides
US8450379B2 (en)	2002-11-05	2013-05-28	Corcept Therapeutics, Inc.	Methods for treating migraine
CA2514966A1 (en)	2003-02-04	2004-08-19	Corcept Therapeutics, Inc.	Antiglucocorticoids for the treatment of postpartum psychosis
US20050080061A1 (en)	2003-07-23	2005-04-14	Corcept Therapeutics, Inc.	Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en)	2003-07-23	2012-01-17	Corcept Therapeutics, Inc.	Antiglucocorticoids for the treatment of catatonia
TW200512181A (en)	2003-09-26	2005-04-01	Tanabe Seiyaku Co	Amide-type carboxamide derivatives
US7951592B2 (en) *	2003-11-10	2011-05-31	The Scripps Research Institute	Compositions and methods for inducing cell dedifferentiation
CA2545020A1 (en) *	2003-11-13	2005-05-26	Pfizer Products Inc.	Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en)	2005-02-14	2012-08-11	Msd Oss Bv	Non steroidal glucocorticoid receptor modulators
WO2007131041A2 (en)	2006-05-02	2007-11-15	Corcept Therapeutics, Inc.	The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
JP4579333B2 (ja) *	2007-02-02	2010-11-10	ファイザー・プロダクツ・インク	三環式化合物およびそれらのグルココルチコイド受容体調節剤としての使用
EP2114970B1 (en)	2007-02-02	2011-08-03	Pfizer Products Inc.	Tricyclic compounds and their use as glucocorticoid receptor modulators

2008
- 2008-01-25 EP EP08702351A patent/EP2114970B1/en active Active
- 2008-01-25 SI SI200830393T patent/SI2114970T1/sl unknown
- 2008-01-25 PL PL08702351T patent/PL2114970T3/pl unknown
- 2008-01-25 MY MYPI20093089A patent/MY146087A/en unknown
- 2008-01-25 GE GEAP200811399A patent/GEP20125404B/en unknown
- 2008-01-25 DK DK08702351.1T patent/DK2114970T3/da active
- 2008-01-25 AP AP2009004942A patent/AP2455A/xx active
- 2008-01-25 PT PT08702351T patent/PT2114970E/pt unknown
- 2008-01-25 AU AU2008211613A patent/AU2008211613B2/en not_active Ceased
- 2008-01-25 MY MYPI20123293 patent/MY153057A/en unknown
- 2008-01-25 UA UAA200907728A patent/UA94639C2/ru unknown
- 2008-01-25 WO PCT/IB2008/000229 patent/WO2008093227A1/en active Application Filing
- 2008-01-25 AT AT08702351T patent/ATE518872T1/de active
- 2008-01-25 CN CN2008800052954A patent/CN101616925B/zh not_active Expired - Fee Related
- 2008-01-25 RS RS20110429A patent/RS51970B/en unknown
- 2008-01-25 MX MX2009008284A patent/MX2009008284A/es active IP Right Grant
- 2008-01-25 CA CA2676670A patent/CA2676670C/en not_active Expired - Fee Related
- 2008-01-25 NZ NZ578638A patent/NZ578638A/en not_active IP Right Cessation
- 2008-01-25 JP JP2009547778A patent/JP4599462B2/ja not_active Expired - Fee Related
- 2008-01-25 BR BRPI0808634-6A patent/BRPI0808634A2/pt not_active IP Right Cessation
- 2008-01-25 KR KR1020097018289A patent/KR101107949B1/ko not_active IP Right Cessation
- 2008-01-25 ES ES08702351T patent/ES2368286T3/es active Active
- 2008-01-25 EA EA200970666A patent/EA016494B1/ru not_active IP Right Cessation
- 2008-01-28 GE GEAP200811398A patent/GEP20125426B/en unknown
- 2008-01-28 ES ES08702358T patent/ES2353822T3/es active Active
- 2008-01-28 CN CN2008800056527A patent/CN101616896B/zh not_active Expired - Fee Related
- 2008-01-28 RS RS20110008A patent/RS51646B/en unknown
- 2008-01-28 MY MYPI20093135A patent/MY148780A/en unknown
- 2008-01-28 KR KR1020097018294A patent/KR101114682B1/ko not_active IP Right Cessation
- 2008-01-28 UA UAA200907730A patent/UA95332C2/uk unknown
- 2008-01-28 PT PT08702358T patent/PT2114888E/pt unknown
- 2008-01-31 PE PE2008000231A patent/PE20081736A1/es not_active Application Discontinuation
- 2008-01-31 US US12/023,323 patent/US7547714B2/en not_active Expired - Fee Related
- 2008-01-31 US US12/023,362 patent/US7598231B2/en not_active Expired - Fee Related
- 2008-02-01 PE PE2008000234A patent/PE20090113A1/es not_active Application Discontinuation
- 2008-02-01 TW TW097104089A patent/TWI347842B/zh active
- 2008-02-01 CL CL200800329A patent/CL2008000329A1/es unknown
- 2008-02-01 AR ARP080100424A patent/AR065134A1/es active IP Right Grant
- 2008-02-01 TW TW097104074A patent/TWI373466B/zh not_active IP Right Cessation
- 2008-02-01 HN HN2008000178A patent/HN2008000178A/es unknown
- 2008-02-01 AR ARP080100425A patent/AR065135A1/es active IP Right Grant
- 2008-02-01 CL CL200800330A patent/CL2008000330A1/es unknown
- 2008-02-01 HN HN2008000179A patent/HN2008000179A/es unknown
2009
- 2009-05-08 US US12/437,704 patent/US8158660B2/en not_active Expired - Fee Related
- 2009-07-20 IL IL199972A patent/IL199972A/en active IP Right Grant
- 2009-07-21 US US12/506,825 patent/US7786097B2/en not_active Expired - Fee Related
- 2009-07-23 CR CR10948A patent/CR10948A/es not_active IP Right Cessation
- 2009-07-23 CR CR10949A patent/CR10949A/es not_active IP Right Cessation
- 2009-07-24 CU CU20090133A patent/CU20090133A7/es active IP Right Grant
- 2009-07-24 CU CU2009000132A patent/CU23848B1/es active IP Right Grant
- 2009-07-29 NI NI200900149A patent/NI200900149A/es unknown
- 2009-07-29 DO DO2009000190A patent/DOP2009000190A/es unknown
- 2009-07-29 NI NI200900148A patent/NI200900148A/es unknown
- 2009-07-30 GT GT200900210A patent/GT200900210A/es unknown
- 2009-07-30 GT GT200900209A patent/GT200900209A/es unknown
- 2009-07-30 SV SV2009003346A patent/SV2009003346A/es not_active Application Discontinuation
- 2009-07-31 TN TNP2009000324A patent/TN2009000324A1/fr unknown
- 2009-07-31 EC EC2009009553A patent/ECSP099553A/es unknown
- 2009-07-31 MA MA32127A patent/MA31117B1/fr unknown
- 2009-07-31 MA MA32128A patent/MA31158B1/fr unknown
- 2009-07-31 EC EC2009009552A patent/ECSP099552A/es unknown
- 2009-07-31 CO CO09079789A patent/CO6220937A2/es active IP Right Grant
- 2009-07-31 CO CO09079796A patent/CO6190603A2/es active IP Right Grant
- 2009-07-31 SV SV2009003349A patent/SV2009003349A/es active IP Right Grant
- 2009-09-01 ZA ZA200906064A patent/ZA200906064B/xx unknown
- 2009-09-01 ZA ZA200906060A patent/ZA200906060B/xx unknown
2010
- 2010-02-12 HK HK10101635.7A patent/HK1135108A1/xx not_active IP Right Cessation
- 2010-12-02 CY CY20101101109T patent/CY1110962T1/el unknown
2011
- 2011-08-17 CY CY20111100784T patent/CY1111758T1/el unknown
- 2011-10-03 HR HR20110702T patent/HRP20110702T1/hr unknown
- 2011-12-21 US US13/333,104 patent/US8445520B2/en not_active Expired - Fee Related
2013
- 2013-04-16 US US13/863,534 patent/US20140142316A1/en not_active Abandoned
2014
- 2014-07-01 US US14/320,674 patent/US8901310B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MY148780A (en)	2013-05-31
CU23824A3 (es)	2011-10-31
GEP20125404B (en)	2012-02-27
GT200900209A (es)	2010-07-22
EA016494B1 (ru)	2012-05-30
KR20090107080A (ko)	2009-10-12
CU20090133A7 (es)	2011-10-31
CU23848B1 (es)	2012-10-15
BRPI0808634A2 (pt)	2014-08-05
CA2676670C (en)	2012-03-13
US7547714B2 (en)	2009-06-16
PL2114970T3 (pl)	2011-11-30
US20090281148A1 (en)	2009-11-12
US20080312294A1 (en)	2008-12-18
US7598231B2 (en)	2009-10-06
AP2009004942A0 (en)	2009-08-31
MY153057A (en)	2014-12-31
EA200970666A1 (ru)	2010-02-26
SV2009003349A (es)	2010-04-13
CO6220937A2 (es)	2010-11-19
HK1135108A1 (en)	2010-05-28
CY1110962T1 (el)	2015-06-11
MA31117B1 (fr)	2010-01-04
UA94639C2 (ru)	2011-05-25
CN101616925A (zh)	2009-12-30
AR065135A1 (es)	2009-05-20
CY1111758T1 (el)	2015-10-07
TWI347842B (en)	2011-09-01
PE20090113A1 (es)	2009-02-13
AP2455A (en)	2012-08-31
GEP20125426B (en)	2012-03-26
GT200900210A (es)	2010-04-05
PT2114888E (pt)	2011-01-04
US7786097B2 (en)	2010-08-31
NZ578638A (en)	2010-12-24
MX2009008284A (es)	2009-08-12
US20080188443A1 (en)	2008-08-07
TW200846325A (en)	2008-12-01
JP4599462B2 (ja)	2010-12-15
RS51646B (en)	2011-10-31
HRP20110702T1 (hr)	2011-10-31
CN101616896A (zh)	2009-12-30
AU2008211613B2 (en)	2013-05-23
ATE518872T1 (de)	2011-08-15
MA31158B1 (fr)	2010-02-01
US20120088802A9 (en)	2012-04-12
TN2009000324A1 (fr)	2010-12-31
US20140142316A1 (en)	2014-05-22
ZA200906064B (en)	2010-05-26
US20120095062A1 (en)	2012-04-19
RS51970B (en)	2012-02-29
UA95332C2 (uk)	2011-07-25
TW200838514A (en)	2008-10-01
DOP2009000190A (es)	2009-08-31
IL199972A (en)	2013-09-30
IL199972A0 (en)	2010-04-15
ZA200906060B (en)	2010-05-26
CR10949A (es)	2009-08-07
HN2008000179A (es)	2010-06-09
PT2114970E (pt)	2011-09-22
CU20090132A7 (es)	2011-10-14
CO6190603A2 (es)	2010-08-19
US8901310B2 (en)	2014-12-02
ES2368286T3 (es)	2011-11-16
US8445520B2 (en)	2013-05-21
AR065134A1 (es)	2009-05-20
AU2008211613A1 (en)	2008-08-07
ES2353822T3 (es)	2011-03-07
MY146087A (en)	2012-06-29
US20100286214A1 (en)	2010-11-11
PE20081736A1 (es)	2008-11-28
US8158660B2 (en)	2012-04-17
WO2008093227A1 (en)	2008-08-07
KR101114682B1 (ko)	2012-03-14
ECSP099552A (es)	2009-08-28
CN101616896B (zh)	2012-07-04
ECSP099553A (es)	2009-08-28
EP2114970A1 (en)	2009-11-11
TWI373466B (en)	2012-10-01
SI2114970T1 (sl)	2011-11-30
NI200900148A (es)	2010-02-15
US20140316139A1 (en)	2014-10-23
CL2008000329A1 (es)	2008-08-08
CR10948A (es)	2009-08-07
NI200900149A (es)	2010-02-15
DK2114970T3 (da)	2011-09-19
CA2676670A1 (en)	2008-08-07
EP2114970B1 (en)	2011-08-03
CN101616925B (zh)	2012-05-23
JP2010517990A (ja)	2010-05-27
SV2009003346A (es)	2010-04-13
KR101107949B1 (ko)	2012-02-08
HN2008000178A (es)	2011-02-25
KR20090108115A (ko)	2009-10-14

Publication	Publication Date	Title
CL2008000330A1 (es)	2008-08-08	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades.
CL2007003502A1 (es)	2008-06-27	Compuestos derivados de pirimidin-amina, moduladores de jnk; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento de artritis reumatoide, asma, diabetes tipo ii, enfermedad de alzheimer, enfermedad de parkinson y apoplejia.
CL2007003755A1 (es)	2008-08-22	Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe
CL2007003423A1 (es)	2008-07-18	Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CL2007002791A1 (es)	2008-04-11	Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri
CL2008001393A1 (es)	2009-05-22	Compuestos derivados de dihidroquinonas y dihidronaftiridinas, inhibidores de jnk; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar artritis reumatoide, asma, diabetes tipo 2, alzheimer, enfermedad de parkinson, hiperproliferacion celular.
CL2008000369A1 (es)	2008-04-18	Compuestos derivados de piridopirimidinonas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dolor, depresion, enfermedades cardiovasculares, enfermedades respiratorias y enfermedades psiquiatricas.
CL2007003666A1 (es)	2008-07-04	Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.
CL2008000703A1 (es)	2008-09-26	Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos.
CL2008000789A1 (es)	2008-10-17	Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
CL2007002904A1 (es)	2008-06-06	Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras.
CL2007002834A1 (es)	2008-05-16	Compuestos derivados de pirazina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos relacionados con inflamacion, tales como artritis, intestino inflamado, alergia,
CL2008000316A1 (es)	2008-08-08	Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara
CL2007003797A1 (es)	2008-07-18	Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
CL2008000612A1 (es)	2008-09-05	COMPUESTOS DERIVADOS DE 3-((1,2,4)TRIAZOLO(4,3-a)PIRIDIN-7-IL)BENZAMIDA; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; Y SU USO PARA TRATAR ARTRITIS REUMATOIDE, LESION POR ISQUEMIA-REPERFUSION, ISQUEMIA CEREBRAL FOCAL, ALZHEIMER, PSORIA
CL2007003804A1 (es)	2008-08-22	Compuestos derivados de indazol; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar condiciones inflamatorias, tales como asma, epoc.
CL2007002446A1 (es)	2008-04-04	Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante.
CL2008000691A1 (es)	2008-09-12	Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
BRPI0818799A2 (pt)	2015-04-22	Composições para o tratamento da doença de parkinson
CL2013001604A1 (es)	2014-07-25	Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
CL2007002330A1 (es)	2008-02-15	Compuestos derivados de oxo aza antraceno; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el rechazo de trasplante, artritis reumatoide, artritis psoriatica, esclerosis multiple, asma, entre otras.
CL2007002099A1 (es)	2008-02-22	Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
CL2008000738A1 (es)	2008-09-22	Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
CL2008000197A1 (es)	2008-08-01	Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.